|Bid||136.00 x 900|
|Ask||136.85 x 900|
|Day's Range||134.49 - 136.76|
|52 Week Range||55.49 - 140.91|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||52.84|
|Earnings Date||Feb 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.64|
The cannabis industry reached another investment milestone when Standards & Poors announced Thursday that it will add the cannabis REIT Innovative Industrial Properties (NYSE: IIPR) to its 600 SmallCap Index next week. IIP is an industry leader in providing real estate capital for the medical cannabis sector. Its addition to the SmallCap Index comes as previous member Amedisys Inc (NASDAQ: AMED) moves up to the MidCap 400 Index.
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
NEW YORK , Feb. 14, 2019 /PRNewswire/ -- S&P SmallCap 600 constituent Amedisys Inc. (NASD: AMED) will replace Aspen Insurance Holdings Ltd. (NYSE: AHL) in the S&P MidCap 400, and Innovative Industrial ...
Amedisys, Inc. (AMED), America’s leading independent home health, hospice and personal care company, commends bipartisan legislation to preserve and expand home health to those who need it the most. “Monday, our congressional champions introduced S. 433 – The Home Health Payment Innovation Act, once again showing support for home health and the value it provides to Medicare beneficiaries,” stated Amedisys President and CEO Paul Kusserow. The bipartisan bill, introduced in Congress on Monday night, would not only preserve but also expand access for millions of Medicare beneficiaries to vitally needed health care services that are delivered to the home.
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Amedisys Inc NASDAQ/NGS:AMEDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMED totaled $349 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Amedisys (AMED) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amedisys, Inc. (AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2018, after the market closes on February 27, 2019. The Company will host an investor conference call to discuss these results at 10:00 a.m. ET on February 28, 2019. To participate on the conference call, please call a few minutes before 10:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
Here are a few ways to invest your money that will help you improve your financial health and mitigate the impacts of any potential adversity.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is for investors who would Read More...
Amedisys, Inc. (the “Company” or “Amedisys”) (AMED), America’s leading independent home health, hospice and personal care company, has closed on its acquisition of Compassionate Care Hospice, a hospice provider headquartered in Parsippany, New Jersey, with 2,300 employees and 53 locations nationwide. Under the terms of the agreement, Amedisys acquired 100 percent of the ownership interests in Compassionate Care Hospice for a fixed price of $340 million, which is inclusive of $50 million in payments related to a tax asset and working capital.
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.